CD34+ Hematopoietic Stem Cell Counts in Alzheimer's Disease: A Meta-Analysis.

IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Diseases (Basel, Switzerland) Pub Date : 2025-01-21 DOI:10.3390/diseases13020025

Vinay Suresh, Malavika Rudrakumar, Anmol Kaur, Victor Ghosh, Poorvikha Satish, Amogh Verma, Priyanka Roy, Mainak Bardhan

{"title":"CD34+ Hematopoietic Stem Cell Counts in Alzheimer's Disease: A Meta-Analysis.","authors":"Vinay Suresh, Malavika Rudrakumar, Anmol Kaur, Victor Ghosh, Poorvikha Satish, Amogh Verma, Priyanka Roy, Mainak Bardhan","doi":"10.3390/diseases13020025","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the presence and quantity of CD34+ hematopoietic stem cells in patients with Alzheimer's disease (AD) through a meta-analysis.Methods: A systematic search of the databases identified the observational and interventional studies reporting baseline CD34+ cell counts in AD patients. The data on mean counts and the measures of variation were extracted. Standardized mean differences (SMDs) were calculated using common and random effects models to compare the CD34+ cell counts between the AD patients and controls. Heterogeneity among the studies was evaluated using tau2, tau, and I2 statistics. The risk of bias was assessed using the Newcastle-Ottawa Scale and the ROBINS-I tool.Patients: Five studies were included, comprising four observational studies and one open-label trial, with a total of 271 participants (139 AD patients and 132 controls).Results: The meta-analysis indicated an increase in CD34+ cell counts of the AD patients when compared to the controls. The common effects model showed a moderate SMD of 0.2964 (95% CI:0.0490-0.5437). However, the random effects model yielded a non-significant SMD of 0.2326 (95% CI: -0.4832-0.9484). Significant heterogeneity was observed among the studies (I2 = 87.1%, p < 0.0001).Conclusion: AD patients may exhibit higher circulating CD34+ cell counts than the controls, but substantial heterogeneity and potential biases limit definitive conclusions.","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":"13 2","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854744/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/diseases13020025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the presence and quantity of CD34+ hematopoietic stem cells in patients with Alzheimer's disease (AD) through a meta-analysis.

Methods: A systematic search of the databases identified the observational and interventional studies reporting baseline CD34+ cell counts in AD patients. The data on mean counts and the measures of variation were extracted. Standardized mean differences (SMDs) were calculated using common and random effects models to compare the CD34+ cell counts between the AD patients and controls. Heterogeneity among the studies was evaluated using tau², tau, and I² statistics. The risk of bias was assessed using the Newcastle-Ottawa Scale and the ROBINS-I tool.

Patients: Five studies were included, comprising four observational studies and one open-label trial, with a total of 271 participants (139 AD patients and 132 controls).

Results: The meta-analysis indicated an increase in CD34+ cell counts of the AD patients when compared to the controls. The common effects model showed a moderate SMD of 0.2964 (95% CI:0.0490-0.5437). However, the random effects model yielded a non-significant SMD of 0.2326 (95% CI: -0.4832-0.9484). Significant heterogeneity was observed among the studies (I² = 87.1%, p < 0.0001).

Conclusion: AD patients may exhibit higher circulating CD34+ cell counts than the controls, but substantial heterogeneity and potential biases limit definitive conclusions.

查看原文本刊更多论文

目的：通过荟萃分析评估阿尔茨海默病（AD）患者体内CD34+造血干细胞的存在和数量：对数据库进行系统检索，确定了报告AD患者CD34+细胞基线计数的观察性和干预性研究。提取了平均计数和变异度量的数据。使用共同效应和随机效应模型计算标准化均值差异（SMDs），以比较AD患者和对照组之间的CD34+细胞计数。使用tau2、tau和I2统计量评估研究之间的异质性。采用纽卡斯尔-渥太华量表和ROBINS-I工具评估偏倚风险：共纳入了五项研究，包括四项观察性研究和一项开放标签试验，共有 271 人参与（139 名 AD 患者和 132 名对照组）：荟萃分析表明，与对照组相比，AD 患者的 CD34+ 细胞计数有所增加。共同效应模型显示，中度 SMD 为 0.2964（95% CI：0.0490-0.5437）。然而，随机效应模型得出的SMD为0.2326（95% CI：-0.4832-0.9484），并不显著。研究之间存在显著的异质性（I2 = 87.1%，P < 0.0001）：AD患者的循环CD34+细胞计数可能高于对照组，但严重的异质性和潜在的偏倚限制了明确的结论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊